ChemoCentryx’s Pancreatic Cancer Product News and Other Important Facts

ChemoCentryx (CCXI) develops new drugs for inflammatory, autoimmune diseases and cancers. The firm’s approach comprises targeting the chemokine and chemoattractant systems with the aim of discovering, developing and commercializing orally-administered therapies for inflammation and malignancy and maybe other disease conditions.
In the News
A few days ago, ChemoCentryx announced positive overall survival (OS) results from Phase Ib clinical trial of its second CCR2 inhibitor drug CCX872 designed for the treatment of locally advanced/metastatic pancreatic cancer and probably other cancers.  

The study . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.